Examining the Use of CDK4/6 Inhibitors in HER2-Negative Breast Cancer
Debu Tripathy, MD, discusses the use of CDK4/6 inhibitors for the treatment of HER2-negative breast cancer based on the results from the phase III MONALEESA-7 trial.
Debu Tripathy, MD, professor and chair, Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses the use of CDK4/6 inhibitors for the treatment of HER2-negative breast cancer, based on results from the phase III MONALEESA-7 trial.
Tripathy says physicians are more likely to use CDK4/6 inhibitors now, especially in patients with visceral disease who may be symptomatic. Previously, the concern was that endocrine therapy was not enough and chemotherapy was necessary. Now, data is showing higher response rates.
Fedratinib Shows Promise in Chronic Neutrophilic Leukemia and MDS/MPN
January 20th 2025In an interview, Andrew Kuykendall, MD, discussed fedratinib’s potential as an effective option for patients with myelodysplastic syndrome/myeloproliferative neoplasms and chronic neutrophilic leukemia.
Read More
